GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Double Bond Pharmaceutical International AB (XSAT:DBP B) » Definitions » Debt-to-Equity

Double Bond Pharmaceutical International AB (XSAT:DBP B) Debt-to-Equity : 0.00 (As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is Double Bond Pharmaceutical International AB Debt-to-Equity?

Double Bond Pharmaceutical International AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was kr0.00 Mil. Double Bond Pharmaceutical International AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was kr0.00 Mil. Double Bond Pharmaceutical International AB's Total Stockholders Equity for the quarter that ended in Mar. 2025 was kr2.90 Mil. Double Bond Pharmaceutical International AB's debt to equity for the quarter that ended in Mar. 2025 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Double Bond Pharmaceutical International AB's Debt-to-Equity or its related term are showing as below:

During the past 10 years, the highest Debt-to-Equity Ratio of Double Bond Pharmaceutical International AB was 0.14. The lowest was 0.00. And the median was 0.02.

XSAT:DBP B's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

Double Bond Pharmaceutical International AB Debt-to-Equity Historical Data

The historical data trend for Double Bond Pharmaceutical International AB's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Double Bond Pharmaceutical International AB Debt-to-Equity Chart

Double Bond Pharmaceutical International AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Double Bond Pharmaceutical International AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Double Bond Pharmaceutical International AB's Debt-to-Equity

For the Biotechnology subindustry, Double Bond Pharmaceutical International AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Double Bond Pharmaceutical International AB's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Double Bond Pharmaceutical International AB's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Double Bond Pharmaceutical International AB's Debt-to-Equity falls into.


;
;

Double Bond Pharmaceutical International AB Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Double Bond Pharmaceutical International AB's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Double Bond Pharmaceutical International AB's Debt to Equity Ratio for the quarter that ended in Mar. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Double Bond Pharmaceutical International AB  (XSAT:DBP B) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Double Bond Pharmaceutical International AB Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Double Bond Pharmaceutical International AB's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Double Bond Pharmaceutical International AB Business Description

Traded in Other Exchanges
N/A
Address
Virdings Alle 32B, Uppsala, SWE, 75450
Double Bond Pharmaceutical International AB is a pharmaceutical company. The company develops and commercializes approaches for the treatment of cancers, infections, autoimmune diseases, and other life-threatening disorders.

Double Bond Pharmaceutical International AB Headlines

No Headlines